Literature DB >> 29868849

Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.

Taishiro Kishimoto1,2,3,4, Katsuhiko Hagi2,5, Masahiro Nitta2,5, Stefan Leucht6, Mark Olfson7, John M Kane2,3,4,8, Christoph U Correll2,3,4,8.   

Abstract

Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs) should improve medication adherence and reduce relapses in schizophrenia. However, meta-analyses of randomized trials and mirror-image studies yielded inconsistent results. Nonrandomized cohort studies with parallel comparisons of LAIs and OAPs offer a third design to examine this issue. We meta-analyzed cohort studies with ≥24 weeks duration and hospitalization data. Primary outcome was hospitalization rate, ie, number of hospitalizations per person-year. Secondary outcomes included hospitalization risk, ie, proportion of patients experiencing ≥1 hospitalizations, all-cause discontinuation, and total hospitalization days. Patient severity and/or chronicity at baseline was also meta-analyzed and explored as a potential effect size moderator. Altogether, 42 studies (n = 101 624; follow-up = 18.6 ± 10.0 mo) were meta-analyzed. LAIs were superior to OAPs regarding hospitalization rate (studies = 15, person-years = 68 009, rate ratio = 0.85, 95% CI = 0.78-0.93, P < .001) and all-cause discontinuations (studies = 10, n = 37 293, risk ratio = 0.78, 95% CI = 0.67-0.91, P = .001), but not regarding hospitalization risk (studies = 33, n = 51 733, risk ratio = 0.92, 95% CI = 0.84-1.00, P = .06), and hospitalization days (studies = 11, n = 21 328, Hedges' g = -0.05, 95% CI = -0.16 to 0.06, P = .39). Illness severity/chronicity was significantly greater in patients prescribed LAIs vs OAPs when all available information was pooled together (studies = 23, n = 61 806, Hedges' g = 0.15, 95% CI = 0.03-0.26, P = .01), but not when examined separately. In summary, this meta-analysis of cohort studies, which included patients that are broadly representative of clinical practice, indicates that LAIs are superior to OAPs. The lack of significant superiority of LAIs for hospitalization risk and hospital days needs to be interpreted in the context of naturalistic treatment selection with subsequently greater illness severity/chronicity in LAI-treated patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29868849      PMCID: PMC5890463          DOI: 10.1093/schbul/sbx090

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  64 in total

1.  Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

Authors:  Larry Alphs; Carmela Benson; Kimberly Cheshire-Kinney; Jean-Pierre Lindenmayer; Lian Mao; Stephen C Rodriguez; H Lynn Starr
Journal:  J Clin Psychiatry       Date:  2015-05       Impact factor: 4.384

2.  Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.

Authors:  Hsue-Wei Chan; Chin-Yu Huang; Wen-Jui Feng; Yung-Chieh Yen
Journal:  Psychiatry Clin Neurosci       Date:  2015-04-21       Impact factor: 5.188

3.  Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.

Authors:  Jimmi Nielsen; Signe O W Jensen; Rasmus B Friis; Jan B Valentin; Christoph U Correll
Journal:  Schizophr Bull       Date:  2014-09-01       Impact factor: 9.306

4.  Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.

Authors:  G Remington; I Khramov
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2001-02       Impact factor: 5.067

5.  Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

Authors:  Robert A Rosenheck; John H Krystal; Robert Lew; Paul G Barnett; Louis Fiore; Danielle Valley; Soe Soe Thwin; Julia E Vertrees; Matthew H Liang
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

6.  A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia.

Authors:  Wayne Macfadden; Yi-Wen Ma; J Thomas Haskins; Cynthia A Bossie; Larry Alphs
Journal:  Psychiatry (Edgmont)       Date:  2010-11

7.  Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

Authors:  John M Kane; Holland C Detke; Dieter Naber; Gopalan Sethuraman; Daniel Y Lin; Richard F Bergstrom; David McDonnell
Journal:  Am J Psychiatry       Date:  2009-12-15       Impact factor: 18.112

8.  Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.

Authors:  Steven C Marcus; Jacqueline Zummo; Amy R Pettit; Jeffrey Stoddard; Jalpa A Doshi
Journal:  J Manag Care Spec Pharm       Date:  2015-09

Review 9.  Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

Authors:  Noam Y Kirson; Peter J Weiden; Sander Yermakov; Wayne Huang; Thomas Samuelson; Steve J Offord; Paul E Greenberg; Bruce J O Wong
Journal:  J Clin Psychiatry       Date:  2013-04-19       Impact factor: 4.384

Review 10.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Authors:  S Leucht; D Arbter; R R Engel; W Kissling; J M Davis
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

View more
  48 in total

1.  Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

Authors:  Takahiro Masuda; Fuminari Misawa; Masayuki Takase; John M Kane; Christoph U Correll
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

2.  Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.

Authors:  Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; John M Kane; Christoph U Correll
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

3.  Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.

Authors:  Qian Cai; Charmi Patel; Edward Kim; Nancy Connolly; Ozgur Tunceli; Antoine C El Khoury
Journal:  Adv Ther       Date:  2019-03-08       Impact factor: 3.845

Review 4.  Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.

Authors:  Luisa Peters; Amanda Krogmann; Laura von Hardenberg; Katja Bödeker; Viktor B Nöhles; Christoph U Correll
Journal:  Curr Psychiatry Rep       Date:  2019-11-19       Impact factor: 5.285

5.  Performance in Practice: Practice Assessment Tool for the Care of Patients With Schizophrenia.

Authors:  Laura J Fochtmann; Jennifer Medicus; Seung-Hee Hong
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

6.  Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.

Authors:  Giovanni Ostuzzi; Federico Bertolini; Federico Tedeschi; Giovanni Vita; Paolo Brambilla; Lorenzo Del Fabro; Chiara Gastaldon; Davide Papola; Marianna Purgato; Guido Nosari; Cinzia Del Giovane; Christoph U Correll; Corrado Barbui
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 49.548

7.  Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.

Authors:  Dee Lin; Philippe Thompson-Leduc; Isabelle Ghelerter; Ha Nguyen; Marie-Hélène Lafeuille; Carmela Benson; Panagiotis Mavros; Patrick Lefebvre
Journal:  CNS Drugs       Date:  2021-04-28       Impact factor: 5.749

8.  Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec.

Authors:  Emmanuel Stip; Jean Lachaine
Journal:  Ther Adv Psychopharmacol       Date:  2018-06-22

9.  Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN).

Authors:  Kai-Chun Yang; Yin-To Liao; Yen-Kuang Yang; Shih-Ku Lin; Chih-Sung Liang; Ya-Mei Bai
Journal:  CNS Drugs       Date:  2021-07-27       Impact factor: 5.749

Review 10.  Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile.

Authors:  Monica Zolezzi; Rawan Abouelhassan; Yassin Eltorki; Peter M Haddad; Mahtab Noorizadeh
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-14       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.